Cart
sales@molnova.com
GPRP acetate
CAS No. 157009-81-9
GPRP acetate( —— )
Catalog No. M29759 CAS No. 157009-81-9
GPRP acetate is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 130 | In Stock |
|
| 50MG | 207 | In Stock |
|
| 100MG | 333 | In Stock |
|
| 200MG | 462 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGPRP acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionGPRP acetate is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).
-
DescriptionGPRP acetate is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number157009-81-9
-
Formula Weight485.53
-
Molecular FormulaC20H35N7O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 125 mg/mL (268.93 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
β-Casomorphin (1-4),...
Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin receptors.
-
PAL-4
PAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.
-
AHR antagonist 5 fre...
AHR antagonist 5 free base is an orally active AHR antagonist with IC50 of approximately 35-150 nM in human and rodent cell lines, and exhibits anticancer activity.
